Antibody Information

General Information of This Antibody

Antibody ID	ANTI0MVFXX
Antibody Name	Trastuzumab (C8)
Organization	Technical University of Darmstadt.; University of Bielefeld.; Lantern Pharma Inc.; The University of Tennessee.; Technical University of Darmstadt.
Synonyms	Trastuzumab (C8) Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized lgG1
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)	Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Tras (C8)-Cp [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	24&#1774 pM	Positive HER2 expression (HER2+++/++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	115&#17748 pM	Positive HER2 expression (HER2+++/++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	732&#177215 pM	Moderate HER2 expression (HER2++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Bladder carcinoma	RT112 cells		CVCL_1670

Tras (C8)-MMAE [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	61&#1779 pM	Positive HER2 expression (HER2+++/++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Breast adenocarcinoma	SK-BR-3 cells		CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2940&#1771674 pM	Positive HER2 expression (HER2+++/++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	10370&#1776865 pM	Moderate HER2 expression (HER2++)
Method Description	Proliferation assays revealed EC50 values in double-digit picomolar range for all constructs on high HER2 expressing cell line SK-BR-3 (Figure 3a, Table 2) which was found to be comparable or significantly lower than for Cp-bearing ADCs found in literature
In Vitro Model	Bladder carcinoma	RT112 cells		CVCL_1670

References

Ref 1	Evaluation of Potency and Specificity of Cryptophycin-Loaded Antibody-Drug Conjugates